Gensight Biologics : Visibilité suspendue au démarrage des AAC
>Cash runway jusqu’au T3 2025 - Gensight publie ses résultats pour le S1 24 dont il ressort les point suivants : 1/ une diminution des dépenses R&D de 46% à 6.3 M€ en raison de la focalisation sur le projet Lumevoq au détriment de GS030 et une diminution des dépense dans les activités de CMC et 2/ une réduction des SG&A de 63% à 0.3 M€ notamment liée au retrait de la demande d’AMM de Lumevoq auprès de l’EMA et à la fin de la préparation du lancement commercial du prod...GenSight Biologics is a clinical-stage biotechnology company based in France. Co. is engaged in discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system by combining a gene therapy-based approach with its core technology platforms of mitochondrial targeting sequence, or MTS, and optogenetics. Co.'s initial focus has been on developing therapies for severe retinal diseases, with the goal of preserving or restoring vision in patients suffering from sight-threatening ophthalmic diseases. Co.'s product pipeline comprises two candidates for the treatment of sight-threatening retinal degenerative diseases, GSO1O and GSO3O.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.